Giovanni Caforio, M.D., has been a vital part of Bristol-Myers Squibb since 2000, starting as a VP and quickly moving up the ranks to become CEO in 2015. His time as CEO has been marked by a focus on aligning...

Giovanni Caforio, M.D., has been a vital part of Bristol-Myers Squibb since 2000, starting as a VP and quickly moving up the ranks to become CEO in 2015. His time as CEO has been marked by a focus on aligning executive compensation with the company's performance. Interestingly, he has opted out of cash bonuses and market stock grants, instead receiving a stable salary that peaked at over $19 million in 2023. Caforio is set to retire from his CEO role in November 2023 but will continue as Executive Chairman to guide the company during this transition. Under his leadership, Bristol-Myers has leaned heavily into cancer therapies and immuno-oncology, gaining a strong foothold in these crucial markets. Known for his medical background, Caforio's approach blends clinical knowledge with corporate strategy, making him an influential figure at Bristol-Myers Squibb. As the company looks towards new leadership, Caforio leaves behind a legacy focused on long-term growth and shareholder alignment.